Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis

NCT01208207 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01208207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2010
Completion date
November 12, 2014
Enrollment
1,015 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

spondylitis, ankylosing